HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ya-Si Xu Selected Research

LC capilliposide

1/2017Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ya-Si Xu Research Topics

Disease

2Neoplasms (Cancer)
02/2017 - 01/2017
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
02/2017 - 01/2017
1Brain Neoplasms (Brain Tumor)
02/2017
1Neoplasm Metastasis (Metastasis)
02/2017

Drug/Important Bio-Agent (IBA)

1AfatinibIBA
02/2017
1Gefitinib (Iressa)FDA Link
01/2017
1LC capilliposideIBA
01/2017